Hill-Rom Holdings Inc (NYSE:HRC)‘s stock had its “buy” rating reaffirmed by KeyCorp in a research report issued to clients and investors on Tuesday, October 17th. They presently have a $82.00 price target on the medical technology company’s stock. KeyCorp’s target price would suggest a potential upside of 4.58% from the stock’s current price.
Several other equities analysts have also recently weighed in on HRC. BidaskClub cut Hill-Rom Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Zacks Investment Research raised Hill-Rom Holdings from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Cantor Fitzgerald assumed coverage on Hill-Rom Holdings in a report on Thursday, June 29th. They issued a “neutral” rating and a $86.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $84.00 price target on shares of Hill-Rom Holdings in a research note on Sunday, July 30th. Finally, Needham & Company LLC assumed coverage on Hill-Rom Holdings in a research note on Thursday, June 29th. They issued a “buy” rating and a $95.00 price target for the company. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $88.57.
Hill-Rom Holdings (HRC) traded up $0.91 during mid-day trading on Tuesday, reaching $78.41. The company had a trading volume of 709,562 shares, compared to its average volume of 485,651. The firm has a market capitalization of $5,104.44, a P/E ratio of 20.07, a PEG ratio of 1.61 and a beta of 1.19. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77.
Hill-Rom Holdings (NYSE:HRC) last released its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The business had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. research analysts forecast that Hill-Rom Holdings will post 4.26 EPS for the current fiscal year.
In other Hill-Rom Holdings news, SVP Andreas G. Frank sold 6,870 shares of Hill-Rom Holdings stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total value of $532,287.60. Following the transaction, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at $1,293,993.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Andreas G. Frank sold 3,940 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total transaction of $306,689.60. Following the sale, the senior vice president now directly owns 16,701 shares in the company, valued at $1,300,005.84. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp lifted its position in Hill-Rom Holdings by 2.7% during the second quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock valued at $133,831,000 after purchasing an additional 43,645 shares during the period. Amalgamated Bank raised its position in shares of Hill-Rom Holdings by 25.7% in the second quarter. Amalgamated Bank now owns 13,108 shares of the medical technology company’s stock worth $1,044,000 after acquiring an additional 2,678 shares during the period. Canada Pension Plan Investment Board raised its position in shares of Hill-Rom Holdings by 42.7% in the second quarter. Canada Pension Plan Investment Board now owns 16,700 shares of the medical technology company’s stock worth $1,329,000 after acquiring an additional 5,000 shares during the period. American Century Companies Inc. raised its position in shares of Hill-Rom Holdings by 1,191.1% in the second quarter. American Century Companies Inc. now owns 110,359 shares of the medical technology company’s stock worth $8,786,000 after acquiring an additional 101,811 shares during the period. Finally, Prudential Financial Inc. raised its position in shares of Hill-Rom Holdings by 6.6% in the second quarter. Prudential Financial Inc. now owns 545,786 shares of the medical technology company’s stock worth $43,449,000 after acquiring an additional 33,714 shares during the period. 81.92% of the stock is currently owned by hedge funds and other institutional investors.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.